Indaptus Therapeutics To Present Pharmacodynamic Immune And Pharmacokinetic Results With Patients From First Cohort Of Ongoing Phase 1 Study Of Decoy20 At Cancer Immunotherapy Meeting
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics, Inc. (NASDAQ:INDP) will present interim data from the first cohort of its Phase 1 INDP-D101 trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) on November 4, 2023. The data showed that each of the first cohort participants experienced transient activation of biomarkers associated with immune responses and expected transient adverse events, both associated with rapid clearance of Decoy20. The company is encouraged by the tolerability of Decoy20 and the evidence for broad immune biomarker activation.
October 31, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indaptus Therapeutics' interim data from the first cohort of its Phase 1 trial of Decoy20 shows promising results, potentially boosting investor confidence in the company's research and development capabilities.
The interim data from the first cohort of Indaptus Therapeutics' Phase 1 trial of Decoy20 shows promising results, with participants experiencing transient activation of biomarkers associated with immune responses and expected transient adverse events. This could boost investor confidence in the company's research and development capabilities, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100